基于假设的洞察力和临床试验更新在阿尔茨海默氏病的发病因子
1Department of Pharmacy, Faculty of Pharmacy, Jadara University, Irbid 21110, Jordan.
CNS & neurological disorders drug targets
|October 23, 2025
概括
阿尔茨海默病 (AD) 治疗方法正在进步,最近的临床试验探索了多目标策略. 天然产品由于其在治疗AD复杂病理方面的有效性而显得有前途.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 老年学是一门学科.
背景情况:
- 阿尔茨海默病 (AD) 是导致痴呆的主要原因,也是老年人群的主要健康问题.
- 衰老过程有助于生理衰退,增加了阿尔茨海默病和其他非传染性疾病 (NCD) 的风险.
研究的目的:
- 审查过去五年对阿尔茨海默病 (AD) 的药物干预措施.
- 专注于AD治疗的I,III和IV期临床试验.
主要方法:
- 进行了对临床试验注册和数据库的系统搜索.
- 包括106个I期,52个III期和13个IV期试验,不包括非药物干预.
- 审查的重点是针对各种AD病变发生途径的治疗方法.
主要成果:
- 确定了一系列针对粉样β聚合,功能障碍,神经炎症,突触损失和代谢失调的治疗方法.
- 阿尔茨海默病的复杂性需要多目标治疗策略,包括组合疗法和新目标.
- 创新的治疗标显示出解决AD多面病原学的潜力.
结论:
- 目前的临床研究揭示了针对阿尔茨海默病的病原性过程的多种疗法.
- 在发现合成分子和天然产品方面的进展为潜在的AD治疗策略提供了机会.
- 自然产品在对抗AD方面特别重要,因为它们具有多个目标效果.
更多相关视频
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
27.9K
04:22Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
Published on: May 20, 2024
1.3K
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
811
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
811
Clinical Trials: Overview
4.6K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.6K
Clinical Trials
10.1K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.1K
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
1.8K
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
1.8K
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
